Last reviewed · How we verify
Inhaled vaporized cannabis
At a glance
| Generic name | Inhaled vaporized cannabis |
|---|---|
| Sponsor | University of Kentucky |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dry Mouth
- Drowsiness
- Cognitive Impairment
Key clinical trials
- Repeated CBD Administration and Cannabis Outcomes (EARLY_PHASE1)
- Acute Effects of Cannabis on Cognition and Affect (PHASE2)
- Cannabis and Opioid Use Disorder (PHASE1)
- Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance (PHASE1)
- Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise (EARLY_PHASE1)
- Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain (PHASE2)
- Brain Mechanisms Supporting Cannabis-induced Pain Relief (EARLY_PHASE1)
- Efficacy of Inhaled Cannabis for Acute Migraine Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled vaporized cannabis CI brief — competitive landscape report
- Inhaled vaporized cannabis updates RSS · CI watch RSS
- University of Kentucky portfolio CI